View of Structure-Based Design and Computational Validation of Novel 1,3,4-Thiadiazole-Peptide Conjugates as Selective Cyclin-Dependent Kinase-2 (CDK2) Inhibitors for Lung Cancer Therapy

Return to Article Details Structure-Based Design and Computational Validation of Novel 1,3,4-Thiadiazole-Peptide Conjugates as Selective Cyclin-Dependent Kinase-2 (CDK2) Inhibitors for Lung Cancer Therapy Download Download PDF